The metastatic microenvironment of breast cancer: Clinical implications

Breast

Volumn 22, Issue S2, 2013, Pages

  Coleman, R E ^a   Gregory, W ^b   Marshall, H ^b   Wilson, C ^a   Holen, I ^a  

^a WESTON PARK HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Adjuvant therapy; Bisphosphonates; Bone marrow microenvironment; Metastasis

Indexed keywords

ALENDRONIC ACID; ANASTROZOLE; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; COLONY STIMULATING FACTOR 1; DENOSUMAB; ETIDRONIC ACID; GOSERELIN; IBANDRONIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR; PAMIDRONIC ACID; RISEDRONIC ACID; TAMOXIFEN; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOGENESIS; CYTOKINE PRODUCTION; DISEASE FREE SURVIVAL; DISSEMINATED CANCER; DRUG ABSORPTION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; SINGLE DRUG DOSE; SURVIVAL RATE; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

ADJUVANT THERAPY; BISPHOSPHONATES; BONE MARROW MICROENVIRONMENT; METASTASIS;

ADMINISTRATION, ORAL; ADULT; AGE FACTORS; AGED; BIOPSY, NEEDLE; BONE MARROW CELLS; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; POSTMENOPAUSE; PREMENOPAUSE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

EID: 84884714562     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.07.010     Document Type: Article

References (44)

1. Taylor J., Hickson J., Lotan T., Yamada D.S., Rinker-Schaeffer C. Using metastasis suppressor proteins to dissect interactions among cancer cells and their microenvironment. Cancer Metastasis Rev 2008, 27:67-73.
2. Horak C.E., Lee J.H., Marshall J.C., Shreeve S.M., Steeg P.S. The role of metastasis suppressor genes in metastatic dormancy. APMIS 2008, 116:586-601.
3. Hu M., Polyak K. Microenvironmental regulation of cancer development. Curr Opin Genet Dev 2008, 18:27-34.
4. Massague J. New concepts in tissue-specific metastases. Clin Adv Hematol Oncol 2003, 1:576-577.
5. Páez D., Labonte M.J., Bohanes P., Zhang W., Benhanim L., Ning Y., et al. Cancer dormancy: a model of early dissemination and late cancer recurrence. Clin Cancer Res 2012, 18:645-653.
6. Demicheli R., Terenziani M., Bonadonna G. Estimate of tumor growth time for breast cancer local recurrences: rapid growth after wake-up?. Breast Cancer Res Treat 1998, 51:133-137.
7. Braun S., Vogl F.D., Naume B., Janni W., Osborne M.P., Coombes R.C., et al. Apooled analysis of bone marrow micrometastasis in breast cancer. NEngl J Med 2005, 353:793-802.
8. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889, 8:98-101.
9. Martínez A.S., Huelsken J. The niche under siege: novel targets for metastasis therapy. JIntern Med 2012 Dec 18, [Epub ahead of print]. 10.1111/joim.12024.
10. Coleman R., Gnant M., Morgan G., Clezardin P. Effects of bone-targeted agents on cancer progression and mortality. JNatl Cancer Inst 2012, 104:1059-1067.
11. Coleman R.E., McCloskey E.V. Bisphosphonates in oncology. Bone 2011, 49:71-76.
12. Ottewell P.D., Monkkonen H., Jones M., Lefley D.V., Coleman R.E., Holen I. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. JNatl Cancer Inst 2008, 100:1167-1178.
13. Saidak Z., Boudot C., Abdoune R., Petit L., Brazier M., Mentaverri R., et al. Extracellular calcium promotes the migration of breast cancer cells through the activation of the calcium sensing receptor. Exp Cell Res 2009, 315:2072-2080.
14. Comen E.A. Tracking the seed and tending the soil: evolving concepts in metastatic breast cancer. Discov Med 2012, 14:97-104.
15. Kim M.Y., Oskarsson T., Acharyya S., et al. Tumour self-seeding by circulating cancer cells. Cell 2009, 139:1315-1326.
16. Käkönen S.M., Mundy G.R. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 2003, 97:834-839.
17. Shimamura T., Amizuka N., Li M., Freitas P.H., White J.H., Henderson J.E., et al. Histological observations on the microenvironment of osteolytic bone metastasis by breast carcinoma cell line. Biomed Res 2005, 26:159-179.
18. Weilbaecher K.N., Guise T.A., McCauley L.K. Cancer to bone: a fatal attraction. Nat Rev Cancer 2011, 11:411-425.
19. Smith M.R., Saad F., Coleman R., Shore N., Fizazi K., Tombal B., et al. Denosumab and bone metastasis-free survival in men with castration-resistant prostate cancer: results of a global phase 3, randomised, placebo-controlled trial. Lancet 2012, 379:39-46.
20. Chen T., Berenson J., Vescio R., Swift R., Gilchick A., Goodin S., et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. JClin Pharmacol 2002, 42:1228-1236.
21. Brown J.E., Ellis S.P., Lester J.E., Gutcher S., Khanna T., Purohit O.P., et al. Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid. Clin Cancer Res 2007, 13:5406-5410.
22. Rogers M.J., Crockett J.C., Coxon F.P., Mönkkönen J. Biochemical and molecular mechanisms of action of bisphosphonates. Bone 2011, 49:34-41.
23. Bosch-Barrera J., Merajver S.D., Menéndez J.A., Van Poznak C. Direct antitumour activity of zoledronic acid: preclinical and clinical data. Clin Transl Oncol 2011, 13:148-155.
24. Ottewell P.D., Lefley D.V., Cross S.S., Evans C.A., Coleman R.E., Holen I. Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model. Int J Cancer 2010, 126:522-532.
25. Holen I., Coleman R.E. Anti-tumour activity of bisphosphonates in preclinical models of breast cancer. Breast Cancer Res 2010, 12:214-226.
26. Stresing V., Fournier P.G., Bellahcène A., Benzaïd I., Mönkkönen H., Colombel M., et al. Nitrogen-containing bisphosphonates can inhibit angiogenesis invivo without the involvement of farnesyl pyrophosphate synthase. Bone 2011, 48:259-266.
27. Rogers T.L., Holen I. Tumour macrophages as potential targets of bisphosphonates. JTransl Med 2011, 9:177.
28. Daubiné F., Le Gall C., Gasser J., Green J., Clézardin P. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. JNatl Cancer Inst 2007, 99:322-330.
29. Coleman R.E., Winter M.C., Cameron D., Bell R., Dodwell D., Keane M.M., et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 2010, 102:1099-1105.
30. Winter M.C., Wilson C., Syddall S.P., Cross S.S., Evans A., Ingram C.E., et al. Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer - a randomised pilot study evaluating biomarkers. Clin Cancer Res 2013, 19:2755-2765.
31. Aft R., Naughton M., Trinkaus K., Watson M., Ylagan L., Chavez-MacGregor M., et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 2010, 11:421-428.
32. Rack B., Jückstock J., Genss E.M., Schoberth A., Schindlbeck C., Strobl B. Effect of zoledronic acid on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res 2010, 30:1807-1813.
33. Solomayer E.F., Gebauer G., Hirnle P., Janni W., Lück H.J., Becker S., et al. Influence of zoledronic acid on disseminated tumour cells in primary breast cancer patients. Ann Oncol 2012, 23:2271-2277.
34. Gnant M., Mlineritsch B., Schippinger W., Luschin-Ebengreuth G., Pöstlberger S., Menzel C., et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. NEngl J Med 2009, 360:679-691.
35. Gnant M., Mlineritsch B., Luschin-Ebengreuth G., Stoeger H., Dubsky P., Jakesz R., et al. Long-term follow-up in ABCSG-12: significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with endocrine-receptor-positive early breast cancer. Cancer Res 2011, 71(24Suppl.). [absS1-2,95s].
36. Coleman R.E., Marshall H., Cameron D., Dodwell D., Burkinshaw R., Keane M., et al. Breast-cancer adjuvant therapy with zoledronic acid. NEngl J Med 2011, 365:1396-1405.
37. Coleman R., de Boer R., Eidtmann H., Llombart A., Davidson N., Neven P., et al. Zoledronic acid (zoledronate) forpostmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol 2013, 24:398-405.
38. Paterson A.H., Anderson S.J., Lembersky B.C., Fehrenbacher L., Falkson C.I., King K.M., et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol 2012, 13:734-742.
39. Mobus V., Diel I.J., Elling D., Harbeck N., Jackisch C., Thomssen C., et al. GAIN (German Adjuvant Intergroup Node Positive) Study: a phase-iii multicenter trial to compare dose dense, dose intense ETC (iddETC) vs. EC-TX and ibandronate vs. observation in patients with node-positive primary breast cancer - 1st interim efficacy analysis. Cancer Res 2011, 71(24 Suppl.). [absS2-4,100s].
40. Powles T., Paterson A., McCloskey E., Schein P., Scheffler B., Tidy A. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer. Breast Cancer Res 2006, 8. R13.
41. Wilson C., Holen I., Coleman R.E. Seed, soil and secreted hormones: potential interactions of breast cancer cells with their endocrine/paracrine microenvironment and implications for treatment with bisphosphonates. Cancer Treat Rev 2012, 38:877-889.
42. Hadji P., Coleman R., Gnant M., Green J. The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis. Ann Oncol 2012, 23:2782-2790.
43. Mocellin S., Keilholz U., Rossi C.R., Nitti D. Circulating tumor cells: the 'leukemic phase' of solid cancers. Trends Mol Med 2006, 12:130-139.
44. Gregory W., Marshall H., Bell R., Cameron D.A., Coleman R.E. Adjuvant zoledronic acid (ZOL) in postmenopausal women with breast cancer and those rendered postmenopausal: results of a meta-analysis. JClin Oncol 2012, 30(suppl.). [Abs 513].